Dr Reddy’s Laboratories on Thursday reported a consolidated net profit of ₹1,593.9 crore for the quarter ended March 31, 2025 (Q4 FY25), marking a 22 per cent increase year-on-year (Y-o-Y) from ₹1,307 crore. Sequentially, profit rose 13 per cent from ₹1,413.3 crore. The company said that new product launches played a key role in achieving double-digit growth in the fourth quarter.
Meanwhile, the pharmaceutical major’s consolidated revenue from operations stood at ₹8,506 crore in Q4 FY25, up 20 per cent from ₹7,083 crore in the same quarter last year. Sequentially, revenue grew 2 per cent from ₹8,358.6 crore in Q3 FY25.
Dr Reddy’s FY25 result
For the entire year, net profit grew marginally by 1.5 per cent to ₹5,654.4 crore from ₹5,568.4 crore in FY24. Moreover, revenue from operations increased from ₹27,916.4 crore in FY24 to ₹32,553.5 crore, registering a 16.6 per cent hike.
Dr Reddy’s Q4 result: Dividend declared
The board of directors have recommended a final dividend of Rs 8 per share, subject to approval of shareholders.
"We achieved double-digit growth across our businesses, driven by successful product launches, increased revenues from key products in the US and the integration of the acquired NRT business. We will continue to strengthen and grow our core businesses through portfolio management and operational excellence, while pursuing strategic partnerships and inorganic growth opportunities," GV Prasad, MD and co-chairman of Dr Reddy’s Lab, said.
Also Read
Shares of Dr Reddy’s Lab were down 0.67 per cent at ₹1156.40 apiece on the BSE at the close of trading on Friday, ahead of the company's earnings announcement.
Dr Reddy’s Q4 result highlights
Profit: ₹1,593.9 crore
Revenue: ₹8,506 crore
Earnings per share: ₹19.13 (basic) ₹19.11 (diluted)
Dr Reddy’s FY25 result highlights
Profit: ₹5,654.4 crore
Revenue: ₹32,553.5 crore
Earnings per share: ₹67.88 (basic) ₹67.78 (diluted)